Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05269628 · ClinicalTrials.gov registry record · Phase 2

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

A Phase 2 study of Pain and Multiple Sclerosis, sponsored by Tiffany J. Braley, MD, MS.

Recruiting
Registry status
Phase 2
Development phase
166
Enrollment target
1
Study location

NCT05269628 is a Phase 2 study of Pain and Multiple Sclerosis that is actively recruiting participants, run by Tiffany J. Braley, MD, MS. The registered enrollment target is 166 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05269628, a Phase 2 study of Pain and Multiple Sclerosis, is actively recruiting participants, sponsored by Tiffany J. Braley, MD, MS.

RECRUITING
Registry status
Phase 2
Development phase
166 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to compare the effects of cannabidiol (CBD), tetrahydrocannabinol (THC), or both, on sleep and pain in persons with multiple sclerosis (MS). Little is known about how CBD and/or THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.

Interventions

  • DRUG Cannabidiol (CBD)
  • DRUG Tetrahydrocannabinol (THC)
  • DRUG Placebo CBD
  • DRUG Placebo THC

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 166 participants
Start Date 2022-03-25
Est. Completion 2027-08-30
Phase Phase 2

Sponsor

Tiffany J. Braley, MD, MS

1 total trials

What the Registry Record Tells You About NCT05269628

The ClinicalTrials.gov registry entry for NCT05269628 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (45% lower). The listed sponsor is Tiffany J. Braley, MD, MS, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 4 interventions - of which Cannabidiol (CBD) is the first listed.

NCT05269628 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT05269628 about?

NCT05269628 is a clinical study titled "Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype". The purpose of this research study is to compare the effects of cannabidiol (CBD), tetrahydrocannabinol (THC), or both, on sleep and pain in persons with multiple sclerosis (MS). Little is known about how CBD and/or THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.

What is the current status of trial NCT05269628?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2022-03-25. Estimated completion is 2027-08-30.

What conditions does trial NCT05269628 study?

This clinical trial studies the following conditions: Pain, Multiple Sclerosis, Sleep.

What interventions are being tested in trial NCT05269628?

The interventions under investigation include: Cannabidiol (CBD) (DRUG), Tetrahydrocannabinol (THC) (DRUG), Placebo CBD (DRUG), Placebo THC (DRUG).

Who is sponsoring clinical trial NCT05269628?

This trial is sponsored by Tiffany J. Braley, MD, MS, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05269628 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.